1. Home
  2. CTMX vs DIN Comparison

CTMX vs DIN Comparison

Compare CTMX & DIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$5.40

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Logo Dine Brands Global Inc.

DIN

Dine Brands Global Inc.

HOLD

Current Price

$38.12

Market Cap

491.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTMX
DIN
Founded
2008
1958
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
596.2M
491.1M
IPO Year
2015
1991

Fundamental Metrics

Financial Performance
Metric
CTMX
DIN
Price
$5.40
$38.12
Analyst Decision
Strong Buy
Hold
Analyst Count
6
6
Target Price
$6.50
$31.67
AVG Volume (30 Days)
3.4M
437.5K
Earning Date
03-05-2026
03-04-2026
Dividend Yield
N/A
2.01%
EPS Growth
50.22
N/A
EPS
0.24
2.24
Revenue
$113,631,000.00
$866,500,000.00
Revenue This Year
N/A
$10.69
Revenue Next Year
N/A
$2.20
P/E Ratio
$22.50
$16.92
Revenue Growth
N/A
6.47
52 Week Low
$0.40
$18.63
52 Week High
$5.70
$39.68

Technical Indicators

Market Signals
Indicator
CTMX
DIN
Relative Strength Index (RSI) 74.56 66.29
Support Level $4.09 $35.65
Resistance Level $4.39 $39.68
Average True Range (ATR) 0.35 1.47
MACD 0.06 0.25
Stochastic Oscillator 85.35 79.93

Price Performance

Historical Comparison
CTMX
DIN

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About DIN Dine Brands Global Inc.

Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.

Share on Social Networks: